On October 5, 2021 Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported pre-clinical data from ONCT-534, an androgen receptor N-terminal-domain-binding small molecule degrader, was accepted for virtual poster presentation at the AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) on October 7-10, 2021(Press release, Oncternal Therapeutics, OCT 5, 2021, View Source [SID1234590822]). Oncternal has conducted a series of preclinical studies in collaboration with the Center for Cancer Research at the University of Tennessee Health Science Center.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ONCT-534 data will be presented as a late-breaking abstract selected for virtual poster presentations and will be available for on-demand viewing in the AACR (Free AACR Whitepaper)-NCI-EORTC platform on October 7, 2021, at 9 a.m. ET.
Abstract Title: Androgen Receptor (AR) N-Terminus-Domain-Binding Small Molecule Degraders for the Treatment of AR Splice Variant-Positive Castration-Resistant Prostate Cancer
Abstract Number: LBA016
"Despite relatively recent advances in treating CRPC, 5-year overall survival remains low, and patients are in need of more effective treatment options" said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. "In preclinical research, ONCT-534 has demonstrated anti-tumor activity in a series of studies and might have the potential to address significant unmet needs related to important tumor resistance mechanisms, including those involving expression of the AR splice variant AR-V7."
About ONCT-534
ONCT-534 (formerly GTx-534) is an investigational, potentially first-in-class androgen receptor (AR) N-terminal-domain-binding small molecule degrader, currently in preclinical development, that was originally discovered by the Center for Cancer Research at the University of Tennessee Health Science Center. Oncternal acquired rights to ONCT-534, which is part of what was previously known as the selective androgen receptor degrader (SARD) program, in Oncternal’s reverse merger with GTx, Inc. in 2019. ONCT-534 has demonstrated preclinical activity in prostate cancer tumor models resistant to approved AR-targeting therapies. Oncternal is currently evaluating strategic development options for ONCT-534 as a potential therapy for castration-resistant prostate cancer (CRPC), LAR-TNBC as well as AR-driven non-oncology indications.
Oncternal is currently seeking to amend the financial terms of a contingent value rights (CVR) agreement relating to the program, subject to approval of a majority in interest of the CVR holders. Among other things, the amendment would increase Oncternal’s share of proceeds from commercialization or other monetization of the program while limiting certain deductions in some cases to those costs incurred after the potential amendment becomes effective. Oncternal intends to provide a programmatic update on ONCT-534 on its earnings call planned for early November 2021.